Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Non-OpeRative MANagement of Rectal Cancer Patients

Early Phase 1

Active, not recruiting

Conditions: Rectal Cancer
Chemoradiotherapy
Watch & Wait

Interventions: Drug: Capecitabine

First Posted Date: 2021-01-06

Last Posted Date: 2024-11-26

Lead Sponsor: Kangbuk Samsung Hospital

Target Recruit Count: 15

Registration Number: NCT04696757

Locations: 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of

Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Inetetamab
Drug: Pyrotinib
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine
Drug: Carboplatin
Drug: Albumin paclitaxel
Drug: Eribulin

First Posted Date: 2020-12-23

Last Posted Date: 2020-12-23

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 71

Registration Number: NCT04681911

Locations: 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

Completed

Conditions: Rectal Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2020-12-22

Last Posted Date: 2024-10-17

Lead Sponsor: Institute of Oncology Ljubljana

Target Recruit Count: 161

Registration Number: NCT04679597

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Phase 3

Terminated

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Sintilimab
Drug: Cisplatin
Drug: 5-fluorouracil
Drug: Ramucirumab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2020-12-19

Last Posted Date: 2023-03-02

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 36

Registration Number: NCT04675983

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

Phase 2

Not yet recruiting

Conditions: Locally Advanced Rectal Cancer

Interventions: Drug: PD-1 antibody
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2020-12-11

Last Posted Date: 2020-12-11

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 40

Registration Number: NCT04663763

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC

Phase 1

Recruiting

Conditions: Metastatic Triple-Negative Breast Carcinoma

Interventions: Drug: Bexarotene
Drug: Capecitabine

First Posted Date: 2020-12-11

Last Posted Date: 2023-10-11

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 12

Registration Number: NCT04664829

Locations: 🇸🇬
National Cancer Center Singapore, Singapore, Singapore

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2

Active, not recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Trastuzumab
Drug: Capecitabine
Drug: Oxaliplatin

First Posted Date: 2020-12-10

Last Posted Date: 2024-11-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 42

Registration Number: NCT04661150

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China
🇨🇳
First Hospital of China Medical University; Surgery, Shenyang City, China
🇨🇳
Tianjin Medical University Cancer Institute & Hospital, Tianjin, China

and more 6 locations

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

Phase 3

Active, not recruiting

Conditions: Advanced/Metastatic Gastroesophageal Adenocarcinoma

Interventions: Biological: Pembrolizumab
Biological: Lenvatinib
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Leucovorin (or Levoleucovorin)
Drug: 5-FU

First Posted Date: 2020-12-10

Last Posted Date: 2024-11-18

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 890

Registration Number: NCT04662710

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0003), Los Angeles, California, United States
🇦🇺
Nepean Hospital ( Site 2305), Kingswood, New South Wales, Australia
🇺🇸
Mount Sinai Hospital ( Site 0051), New York, New York, United States

and more 174 locations